Global Plasma Fractionation Market Overview and Forecast
The plasma fractionation market was valued at USD 38.50 billion in 2025 and is expected to reach USD 73.18 billion by 2033, registering a CAGR of 8.36% during the forecast period of 2026–2033. Market growth is primarily driven by increasing demand for plasma-derived therapies such as immunoglobulins, albumin, and coagulation factors. Rising prevalence of immunodeficiency, hemophilia, and chronic diseases globally continues to expand the market footprint, particularly in neurology and musculoskeletal disorders.
The market benefits from technological innovations in fractionation methods and the expansion of plasma collection centers, which enhance supply chain efficiency and product availability.
Key Growth Drivers in Plasma Fractionation Market
Rising Plasma Collection and Fractionation Capacity
Global demand for plasma-derived therapies has prompted major players to expand plasma donation centers and fractionation plants. Companies like CSL Behring, Takeda, Octapharma, and Grifols are investing heavily in infrastructure to meet growing needs. For example, Takeda expanded its Los Angeles fractionation facility to cater to global demand, while Octapharma invested USD 200 million in Vienna, increasing production capacity by 50% and doubling packaging speed.
Technological Advancements Driving Efficiency
Plasma fractionation has evolved with advanced separation and purification techniques, including chromatography, depth filtration, and viral inactivation methods. These innovations improve protein yield, safety, and purity. In March 2025, Octapharma became the sole fractionator in the UK Plasma‑for‑Medicines programme using UK-sourced non-paid plasma, marking a milestone in supply chain resilience.
Expanding Applications and Regulatory Compliance
The growth of immunoglobulin therapy, albumin applications, and coagulation factors is complemented by rigorous regulatory oversight. Agencies such as FDA, EMA, and PMDA enforce strict quality, safety, and efficacy standards, ensuring patient safety while influencing development timelines. Collaborative efforts between biopharmaceutical companies and research institutions further accelerate innovation.
Discover Market Shifts: Secure Your Sample Report Now: https://www.snsinsider.com/sample-request/2992
Market Segmentation Insights
By Product
Immunoglobulins dominate the market with a 64.10% share in 2025, largely due to applications in immune deficiency and neurological disorders. Albumin is expected to grow fastest, driven by its increasing use in critical care, liver diseases, and surgical procedures.
By Method
Chromatography leads the market, offering superior purity and selectivity for plasma protein separation. Centrifugation is projected to grow fastest, particularly in early-stage plasma processing and decentralized fractionation systems.
By Application
Neurology accounts for the largest market share due to extensive use of immunoglobulins in treating chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, and multifocal motor neuropathy. Oncology is the fastest-growing segment, as albumin-based chemotherapies and immunoglobulins enhance cancer treatment effectiveness.
By End-Use
Hospitals and clinics dominate with a 54.11% share, given the intravenous administration of plasma-derived therapies. Clinical research is expected to see the fastest growth, fueled by R&D in new therapeutic indications, combination therapies, and rare disease treatments.
Regional Market Insights
North America
North America dominates the market with a 51.62% share in 2025. The region benefits from an extensive network of plasma collection centers, strong manufacturing infrastructure, and key players such as CSL Behring, Grifols, and Takeda. Favorable reimbursement policies and early adoption of advanced fractionation technologies further support market growth.
Asia Pacific
The Asia Pacific market is expanding due to increased healthcare investments, rising disease diagnosis rates, and improved access to plasma-derived therapies. Rapid expansion of plasma collection and processing infrastructure in China, India, and Japan is driving strong growth.
Europe
Europe maintains steady growth due to established biopharmaceutical infrastructure, supportive regulatory environments, and rising demand for plasma-derived therapies in immunology, hematology, and neurology. Investments in local plasma processing and R&D are bolstering production capabilities.
Middle East, Africa, and Latin America
Growth in Latin America and the Middle East & Africa is moderate, driven by gradual development of healthcare infrastructure, awareness of plasma therapy benefits, and strategic collaborations with global manufacturers to standardize approvals and scale production.
Competitive Landscape
Leading companies in the Plasma Fractionation Market include Octapharma AG, Takeda Pharmaceutical Company Limited, CSL Behring, Grifols S.A, Kedrion Biopharma Inc., Bio Products Laboratory, Sanquin, LFB S.A., China Biologic Products Holdings Inc., Green Cross Corporation, Syntegon, Hualan Bio, Intas Pharmaceuticals Ltd., Biotest AG, Shanghai RAAS Blood Products Co., Ltd., Kamada Ltd., Haemonetics Corporation, Mitsubishi Tanabe Pharma Corporation.
These players are investing in plant expansions, automation, and process optimization to meet growing global demand for plasma-derived therapies. For instance, CSL Behring inaugurated its “Phoenix” fractionation plant in Germany with a USD 470 million investment, significantly boosting production capacity.
Future Outlook
The Plasma Fractionation Market is poised for continued expansion, driven by increasing global demand for plasma-derived therapies, technological advancements in fractionation, and the growth of clinical research initiatives. Emerging markets in Asia Pacific and ongoing expansions in North America and Europe are expected to further bolster market growth.
Recombinant therapies, enhanced safety protocols, and decentralized plasma collection models are anticipated to shape the next phase of innovation, enabling broader patient access and more resilient supply chains.
Conclusion
The global Plasma Fractionation Market is experiencing robust growth, projected to reach USD 73.18 billion by 2033 at a CAGR of 8.36%. Growth is fueled by rising demand for immunoglobulins, albumin, and coagulation factors, supported by technological innovation, expanded plasma collection networks, and increasing clinical research activities. Market players are strategically investing in infrastructure and R&D to meet global therapy needs, while regulatory compliance ensures patient safety. With rising awareness and adoption across regions, the plasma fractionation sector is poised to maintain its upward trajectory in the coming decade.
Other Trending Reports
